Introduction
LUTS, BPE and OAB are interrelated to an extent that remains unclear. In the presence of BOO, OAB was long thought to be the result of compensated detrusor hypertrophy to overcome the infravesical obstruction. 1 However, alternative mechanisms could be involved, as OAB might occur in the absence of BOO, while 50% of men with BPE have OAB symptoms and 30% of men with BPE and OAB continue to be symptomatic even after prostatectomy.
Combination therapy of antimuscarinics with a-blockers is an approved therapeutic option for OAB related to BPE. 5 Randomized trials have shown the superiority of combination treatment over monotherapy in improving patients' symptoms and QoL, as well as key urodynamic parameters, without significantly affecting Q max and PVR. 1, [6] [7] [8] [9] Monotherapy with either an antimuscarinic or a-blocker produced inferior or no improvements. 10 Antimuscarinics exert their effect through MAChRs. It would be expected that the beneficial clinical effect would result from their acknowledged mechanism of action on cholinergic pathways associated with the bladder. 3 However, all five MAChR subtypes have been identified in the prostate, as well as in the bladder. 11, 12 It has been suggested that prostate MAChRs are involved in prostatic secretion, growth and contraction. 12 Based on these clinical and preclinical data, we carried out a pilot study to investigate a possible effect of oral antimuscarinics on morphometric parameters of the prostate, along with their expected effect on urinary bladder function.
Methods

Study design and patient population
This was a prospective, open-label, active comparator controlled, randomized study carried out between October 2013 and June 2015 (ISRCTN11552705). The study was approved by the institutional review board and the local university's ethics committee, and was carried out in accordance with the Declaration of Helsinki.
Participants were randomized into two groups to receive either tamsulosin (Tamsulosin OCAS 0.4 mg; Astellas Pharma, Marousi, Greece) alone or in combination with solifenacin 5 mg (Astellas Pharma), with a 1:1 allocation ratio. The randomization process was completed by SPSS 19 .0 software (IBM, Armonk, NY, USA). Titration of the solifenacin dose to 10 mg was possible in patients who had inadequate symptom control after 4 weeks.
Eligible patients were treatment-na€ ıve men aged ≥50 years with predominantly storage LUTS (IPSS storage subscore ≥ voiding subscore and score ≥3 in the IPSS urgency question), and at least three urgency episodes per 24 h documented in a 3-day bladder diary, prostate volume ≥30 mL, Q max ≥10 mL/s, PVR ≤100 mL and PSA ≤4 ng/mL. Patients with suspicious rectal examination and/or PSA values 4-10 ng/ mL were included only after negative prostate biopsy. Exclusion criteria were: neurogenic LUT dysfunction; a history of malignancy; any contraindication to the use of a-blockers or antimuscarinics; metabolic conditions or use of medications that might affect LUT function, including phosphodiesterase-5 inhibitors; psychiatric illnesses; chronic kidney, hepatic or cardiac failure; a history of urinary stone disease; urethral stricture; acute UTI or a history of recurrent UTIs; positive urine culture; and microscopic hematuria, proteinuria or glucosuria. Patients with pyuria were included only after a negative urine culture.
Clinical assessments
After screening in male LUTS clinics with physical examination, history, IPSS questionnaire, transvesical ultrasound and uroflowmetry, as per routine, potential candidates were given the study information pack and a 3-day bladder diary to return at 2 weeks. Eligible patients as per the study criteria were considered for recruitment. After written informed consent, participants were randomized to either of the two study groups.
All randomized participants completed the IPSS and OABq questionnaires, were submitted to transrectal and transvesical ultrasonography, uroflowmetry, pressure-flow study, and PSA measurement both at baseline and at study completion (week 26). Interim follow up included questionnaires, uroflowmetry and transvesical ultrasonography at 4 and 12 weeks. A physical examination, blood pressure and heart rate measurements were carried out during every visit. The bladder diary was repeated at week 26. Micturition frequency, urgency and nocturia episodes are presented as the average of 3 days. AEs were monitored throughout the study; their severity and causal relationship to study medications was assessed.
At study completion, patients were asked whether they would like to continue on medical therapy or undergo prostatectomy (transurethral resection for prostates <80 mL or open procedure for prostates >80 mL).
Study end-points and parameters
The primary end-point was the percentage change of total prostate volume as measured by TRUS from baseline to week 26. The secondary end-points included changes in adenoma volume, prostate vascularity, micturition episodes per 24 h, IPSS and OABq scores, and urodynamic parameters.
The ultrasonographic study was carried out using the General Electric Logiq 3 ultrasound machine (General Electric, Boston, MA, USA), applying the 7.5-MHz transrectal probe with the patient in the left lateral decubitus position. The total prostate and adenoma volumes were measured by two methods: the ellipsoid model and the planimetric volumetric technique from a series of transverse prostate image sections. 13 Planimetric volumetry is an acknowledged technique that correlates well with radical prostatectomy specimens and is not influenced by asymmetrically hypertrophied lobes or by a median lobe.
14 Sections started from the apex towards the base, with a 5-mm step providing approximately 8-12 images per patient. A stepper was used to ensure a proper step. A similar sequence of images was obtained using power Doppler to calculate vascularity based on color pixel density, as previously described. 15 The pixels within every section image were considered. The total number of prostate pixels was given from the 3-D model. Prostate vascularity was the percentage of color pixel density to the total prostate surface ([color pixel density/total prostate pixels] 9 100). Two experienced urologists (VS, VS) carried out the ultrasonographic study according to the Standardization of Bladder Ultrasonography as per ICS protocols. 14 We used the validated Greek versions of IPSS, OABq and the short OAB-V8 version questionnaires. Total IPSS, storage and voiding subscale scores were calculated. QoL was assessed by the relevant IPSS question. The 62-item OABq was completed at baseline and at completion, whereas the first eight questions were assessed at the interim follow ups. Good Urodynamic Practice as per ICS was applied using a computerized urodynamic system (Dantec Duet Urodynamic equipment; Dantec Dynamics, Portbury, UK) for both uroflowmetry and pressure-flow studies. 16 P-F studies were carried out in the sitting position, while uroflowmetry was left at patient preference. The BOOI, BCI, URI and BVE were calculated. PVR was assessed by ultrasound.
Statistical analysis
Descriptive statistical analysis was carried out for all study data. Continuous variables were summarized with the use of descriptive measures (mean, SD, range). An ANCOVA was used to adjust for pretreatment differences. Extreme outliers (>4 SDs) were removed from the analysis. Point estimations were presented with 95% CIs. The Wilcoxon test for independent samples was used to examine the difference in distribution values of continuous variables before and after treatment. All statistical tests were two-sided and were carried out at a 0.05 significance level. Analysis was carried out with SAS version 9.3 (SAS Institute Inc., Cary, NC, USA).
Sample size calculation was based on data of prostate volume changes from the CombAT study, where the mean prostate volume at baseline was 55.8 mL (SD 24.18) for the monotherapy group and 54.7 mL (SD 23.51) for the combination group. 17 There was an increase of 4.6% in the tamsulosin group, and a 27.3% decrease in the tamsulosin and dutasteride group. Based on these results, we aimed to detect a difference ≥30% between the two groups in the present study. Using a two-sample t-test at a (two-sided) a of 5%, we calculated that a power of 80% would be achieved with 60 randomized participants. We aimed to recruit an additional 15 patients to cover for a 25% dropout rate (total 75 patients).
Results
A total of 80 patients were recruited, but just 69 fulfilled the inclusion criteria and were randomized (1:1) to monotherapy (n = 34) or combination therapy (n = 35). The sample (n = 69) provides >85% statistical power to the study. A total of 63 (n = 63) patients completed the study (monotherapy n = 31, combination therapy n = 32; Fig. 1 ). All patients were of Caucasian origin. At randomization, the two groups were comparable for demographic characteristics (Table 1) , questionnaire scores, bladder diary and urodynamic parameters (Table 2) .
At baseline, both groups were comparable for total prostate volume (48.93 AE 13.6 mL vs 52.63 AE 31.0 mL) and adenoma volume (24.45 AE 10.2 mL vs 28.37 AE 21.4 mL). After treatment, an increase in total prostate volume (9.2%) was noted in the monotherapy group, as opposed to a decrease (À9.5%) in the combination group (comparative P < 0.001). Similar changes were found in adenoma volume (+17.4% vs À12.5%, P < 0.001; Fig. 2 ). At baseline, prostate vascularity was 1.3 AE 1.1% for the monotherapy group and 1.7 AE 0.9% for the combination therapy group. At the end of the treatment, there was a marked increase (149.3%) in the monotherapy group corresponding to 1.9 AE 1.0% of total prostate (Fig. 3a,b) . By contrast, vascularity was reduced in the combination group by 19.8%, corresponding to 1.0 AE 0.6% of total prostate area (Fig. 3c,d ). Bladder wall thickness was equally reduced in both groups after treatment (2.8 AE 0.6 vs 2.7 AE 0.9; P = 0.629).
Just seven patients were titrated to solifenacin 10 mg. Comparisons between the non-titrated and titrated subgroups did not show a clear dose-related response in any of the morphometric parameters. Both groups were significantly different from tamsulosin monotherapy (P < 0.001). These results should be interpreted with caution.
Changes in the study parameters are presented in Table 2 and Figure 4 . Both groups improved significantly in the bladder diary parameters compared with baseline (P < 0.001), but combination therapy showed a trend for better control of frequency, urgency and nocturia (comparative P = 0.067, P = 0.117 and P = 0.057, respectively). Combination therapy induced greater improvements in the storage subscale and OABq scores when compared with monotherapy (P = 0.023 and P = 0.023, respectively), whereas monotherapy improved the IPSS voiding subscore more significantly (P < 0.001). Tamsulosin improved the Q max (P = 0.006), whereas combination therapy induced a non-significant reduction (P = 0.733; comparative P = 0.042). BOOI improved in both groups, although more significantly in the combination group (À14.1% vs À24.4%, P = 0.034), whereas BCI was improved in the monotherapy group (+4.1% vs À2.5%, P = 0.214). PVR decreased after monotherapy, but increased in the combination group (P = 0.003). No case of retention was recorded, but three patients taking solifenacin 10 mg were found to have PVR >100 mL at study completion (140, 170 and 280 mL vs 30, 100 and 50 mL at baseline, respectively). They discontinued solifenacin and opted for prostatectomy. PSA values increased in both groups, but changes were not significantly different between the two groups (+23.8% vs +12.5%, P = 0.359).
There were no major AEs related to pharmacotherapy. From the monotherapy group, one patient withdrew from the study as a result of bothersome lightheadedness, while two patients complained of moderate dyspepsia. In the combination therapy group, six patients complained of dry mouth and dry eyes, and five of constipation. No treatment-related UTI was recorded. Three patients were found to have PVR >100 mL at the completion of the study without any concomitant upper urinary tract changes.
After study completion, 26 of 31 (83.9%) patients from the monotherapy group, as opposed to 15 of 32 (46.9%) patients from the combination therapy group, opted to undergo prostatectomy in due course (P < 0.001).
Discussion
The results of the present pilot study provide the first evidence for an effect of antimuscarinics -namely solifenacin -on prostate morphometric parameters. The combination of solifenacin with tamsulosin, but not tamsulosin monotherapy, reduced both prostate and adenoma volumes, as well as prostate perfusion, as vascularity of the prostate was reduced. Despite the small sample size, the study was adequately powered to reproduce findings of previous studies, and the 6-month follow-up period renders it one of the longest in the field of combination therapy of male LUTS.
Sympathomimetics induce prostate hyperplasia in rodents as a result of reduced cellular apoptotic rates rather than increased cellular proliferation. 18 By contrast, the quinazoline-based ablockers (terazosin and doxazosin) were found to exert a potent apoptotic effect against prostate cancer cells through an a1-adrenoreceptor-independed pathway, caspace-3 and enhanced expression of transforming growth factor-b1. [18] [19] [20] This effect is mediated by the quinazoline nucleus, as tamsulosin (sulphonamide-based a-blocker) fails to exert similar apoptotic action. 21 It is not a novelty that a-blockers influence prostate perfusion. Pingerra et al. found that tamsulosin monotherapy increases prostate vascularity by 132.8%, and concluded that Excluded from analysis (due to inadequate data) (n = 3)
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Follow-up the clinical effect of a-blockers might be related to the improvement of chronic ischemia. 15 In the present study, we found an increase of +149.3% after tamsulosin monotherapy, and a reduction of À19.8% after tamsulosin-solifenacin combination treatment. The apparent discrepancy between prostate perfusion changes and changes in clinical outcomes in our study might be due to the acknowledged beneficial effect of antimuscarinics on bladder function, which is mediated through the bladder MAChRs. The possibility and the extent of a simultaneous effect through prostate MAChRs remain unknown.
To our knowledge, there is no published study on the effect of antimuscarinics on prostate and LUT blood flow. However, men taking antimuscarinics were found to be at greater risk for erectile dysfunction, probably through eNOS inhibition on the endothelium and smooth muscle of the corpora cavernosa. 22 In addition, all five MAChRs are present in the endothelium and smooth muscle cells of small arteries. 23 Cholinergic innervation mediates an endothelium-dependent vasodilation and an endothelium independent vasoconstriction in arterioles. 24 Whether solifenacin affects blood flow through eNOS inhibition or vasoconstriction requires further investigation.
In the monotherapy group, the total prostate volume was increased by 9.2% and adenoma volume by 17.4%. It is not known whether this is the result of prostatic epithelial growth or of reduced apoptotic action. The increased vascularity noted in this group could have influenced prostate dimensions, which in turn could have had an impact in volume measurement. By contrast, in the combination therapy group, a reduction of total prostate volume by À9.5% and of adenoma volume by À12.5% was noted. Further to these changes, prostate perfusion was reduced in this group. The human prostate expresses MAChRs at densities exceeding those of a1-adrenoreceptors, 12 with a preponderance of the M1 subtype on prostatic epithelium and a smaller population of M2 subtype found on stromal cells. 12, 25 In primary epithelial and stromal cultures of BPE patients, M1, M3 and M5 receptors were expressed in the prostatic epithelium and M2 and M4 receptors in the prostatic stroma. 26 In cell cultures, carbachola muscarinic receptor agonist -stimulates prostatic growth of prostate cancer cells through increased DNA synthesis. 27 This mitogenic response is mediated by M3 receptors. 27 In addition, intraprostatic injection of botulinum toxin reduces prostate size due to increased apoptosis and reduced cell proliferation of both epithelial and stromal cells. 28 Recent evidence suggests a mechanism involving impairment of autonomic innervation through inhibition of acetylcholine and noradrenaline. [29] [30] [31] Despite the intriguing morphometric changes noted in the present study, a rise in PSA values was detected in both arms (group I +0.26 ng/dL, group II +0.2 ng/dL). This is an apparent discrepancy, as the decrease in adenoma volume in the combination group would predispose to a subsequent PSA reduction. It might be partly explained by a lack of solifenacin influence on prostate secretory mechanisms. As M1 receptors are thought to be involved in prostatic epithelial cells secretions, our finding might indicate an M1-independent effect of solifenacin on the human prostate. 32 Interestingly, the absolute percentage change in PSA was lower in the combination group. Thus, the non-significant difference between the two groups might be also due to the small sample size, as the study was not powered to identify changes in PSA level.
Both monotherapy and combination therapy showed beneficial effects on male LUTS in accord with results of previous studies. Marked symptomatic improvement was documented in all questionnaires used in both groups. The storage subscale of IPSS and the OABq scores were more improved in the combination therapy group, whereas the voiding subscale of IPSS was improved in the monotherapy group. That signifies even better storage symptoms control by solifenacin. As more patients in the monotherapy group were submitted to prostatectomy after the end of study, as opposed to the combination therapy group, it becomes evident that a-blocker monotherapy provides inadequate symptomatic control, and that dual therapy is more beneficial in the mid term for patients in whom storage symptoms constitute a major LUTS component. This result bears implications for clinical practice, which need to be confirmed in larger, longitudinal studies. Tamsulosin monotherapy improved flow rates, whereas combination treatment increased cystometric capacity and PVR. No patient went into retention or required catheterization, but solifenacin was discontinued in the cases of increased PVR at end-of-study. Questionnaire graphic results show significant improvements were noted in both study arms. The IPSS storage subscore and OABq score improved more in the combination therapy group, whereas monotherapy produced higher improvement in the IPSS voiding subscore. (c) Non-invasive urodynamic parameters showed a more significant improvement in Q max in the monotherapy group, whereas the combination treatment group had a more marked change in the mean voided volume, but also in PVR. (d) Mean percentage changes in pressure-flow study parameters and indices showed improvements in both study arms. BOOI was significantly reduced in the combination group as compared with monotherapy.
The limitations of the present study were the lack of a placebo arm, the lack of a solifenacin monotherapy arm and, possibly, its small sample size, although the study was adequately powered to detect significant differences in the primary outcome. In addition, the study of parameters, such as prostate vasculature resistance index and bladder wall Doppler values, could add to a future investigation. Finally, measurements of the study parameters at multiple time-points would certainly add to the reproducibility of results, but this might significantly enhance patients' discomfort from invasive investigations.
A strength of the present study was the homogenous sample, in terms of age, race and symptoms severity. Furthermore, the measurement of several parameters provides a reasonable insight of both subjective symptoms and objective findings.
Briefly, the results of this pilot study suggest an effect of solifenacin on morphometric properties of the human prostate, as a combination of solifenacin with tamsulosin reduced the total prostate and adenoma volumes as well as vascularity contrary to the findings with tamsulosin monotherapy. The results need to be confirmed in larger longitudinal studies, while mechanistic studies could clarify whether these findings reflect a molecular effect of antimuscarinics on the prostate, in parallel with their expected bladder effect.
